The B-cell-specific transcription factor and master regulator Pax5 promotes epstein-barr virus latency by negatively regulating the viral immediate early protein BZLF1

Journal of Virology

Volumn 87, Issue 14, 2013, Pages 8053-8063

  Raver, Ryan M ^a,b   Panfil, Amanda R ^a,b,c   Hagemeier, Stacy R ^a   Kenneya, Shannon C ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; IMMEDIATE EARLY PROTEIN BZLF1; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR PAX5;

AMINO TERMINAL SEQUENCE; ARTICLE; BURKITT LYMPHOMA; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DIMERIZATION; DOWN REGULATION; EPITHELIUM CELL; EPSTEIN BARR VIRUS; IN VIVO STUDY; INHIBITION KINETICS; LYMPHOMA CELL LINE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REPORTER GENE; VIRUS GENOME; VIRUS LATENCY; VIRUS PARTICLE; VIRUS REACTIVATION; VIRUS RELEASE;

B-CELL-SPECIFIC ACTIVATOR PROTEIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DNA PRIMERS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION, VIRAL; GENETIC VECTORS; HERPESVIRUS 4, HUMAN; HUMANS; LENTIVIRUS; PLASMIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANS-ACTIVATORS; VIRUS LATENCY;

EID: 84880315168     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00546-13     Document Type: Article

References (74)

1. Kieff E, Rickinson AB. 2007. Epstein-Barr virus and its replication, p 2603-2654. In Knipe DM, Howley PM (ed), Fields virology, 5th ed. Lippincott/The Williams & Wilkins Co, Philadelphia, PA.
2. Zur Hausen H, Schulte-Holthausen H, Klein G, Henle W, Henle G, Clifford P, Santesson L. 1970. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 228:1056-1058.
3. Souza TA, Stollar BD, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. 2005. Peripheral B cells latently infected with Epstein-Barr virus display molecular hallmarks of classical antigen-selected memory B cells. Proc. Natl. Acad. Sci. U. S. A. 102:18093-18098.
4. Laichalk LL, Thorley-Lawson DA. 2005. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J. Virol. 79:1296-1307.
5. Yu X, Wang Z, Mertz JE. 2007. ZEB1 regulates the latent-lytic switch in infection by Epstein-Barr virus. PLoS Pathog. 3:e194. doi:10.1371/journal.ppat.0030194.
6. Bhende PM, Dickerson SJ, Sun X, Feng WH, Kenney SC. 2007. X-boxbinding protein 1 activates lytic Epstein-Barr virus gene expression in combination with protein kinase D. J. Virol. 81:7363-7370.
7. + by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program, and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas. Blood 117:5907-5917.
8. Feederle R, Kost M, Baumann M, Janz A, Drouet E, Hammerschmidt W, Delecluse HJ. 2000. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J. 19:3080-3089.
9. Adamson AL, Kenney SC. 1998. Rescue of the Epstein-Barr virus BZLF1 mutant, Z(S186A), early gene activation defect by the BRLF1 gene product. Virology 251:187-197.
10. Chang LK, Chuang JY, Nakao M, Liu ST. 2010. MCAF1 and synergistic activation of the transcription of Epstein-Barr virus lytic genes by Rta and Zta. Nucleic Acids Res. 38:4687-4700.
11. Cox MA, Leahy J, Hardwick JM. 1990. An enhancer within the divergent promoter of Epstein-Barr virus responds synergistically to the R and Z transactivators. J. Virol. 64:313-321.
12. Darr CD, Mauser A, Kenney S. 2001. Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation. J. Virol. 75: 6135-6142.
13. Farrell PJ, Rowe DT, Rooney CM, Kouzarides T. 1989. Epstein-Barr virus BZLF1 transactivator specifically binds to a consensus AP-1 site and is related to c-fos. EMBO J. 8:127-132.
14. Flemington E, Speck SH. 1990. Autoregulation of Epstein-Barr virus putative lytic switch gene BZLF1. J. Virol. 64:1227-1232.
15. Gruffat H, Manet E, Rigolet A, Sergeant A. 1990. The enhancer factor R of Epstein-Barr virus (EBV) is a sequence-specific DNA binding protein. Nucleic Acids Res. 18:6835-6843.
16. Hardwick JM, Lieberman PM, Hayward SD. 1988. A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J. Virol. 62:2274-2284.
17. Kenney S, Kamine J, Holley-Guthrie E, Lin JC, Mar EC, Pagano J. 1989. The Epstein-Barr virus (EBV) BZLF1 immediate-early gene product differentially affects latent versus productive EBV promoters. J. Virol. 63: 1729-1736.
18. Lieberman PM, Hardwick JM, Sample J, Hayward GS, Hayward SD. 1990. The zta transactivator involved in induction of lytic cycle gene expression in Epstein-Barr virus-infected lymphocytes binds to both AP-1 and ZRE sites in target promoter and enhancer regions. J. Virol. 64:1143-1155.
19. Quinlivan EB, Holley-Guthrie EA, Norris M, Gutsch D, Bachenheimer SL, Kenney SC. 1993. Direct BRLF1 binding is required for cooperative BZLF1/BRLF1 activation of the Epstein-Barr virus early promoter, BMRF1. Nucleic Acids Res. 21:1999-2007.
20. Rooney CM, Rowe DT, Ragot T, Farrell PJ. 1989. The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle. J. Virol. 63:3109-3116.
21. Liu P, Speck SH. 2003. Synergistic autoactivation of the Epstein-Barr virus immediate-early BRLF1 promoter by Rta and Zta. Virology 310: 199-206.
22. Zalani S, Holley-Guthrie E, Kenney S. 1996. Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Proc. Natl. Acad. Sci. U. S. A. 93:9194-9199.
23. Countryman J, Jenson H, Seibl R, Wolf H, Miller G. 1987. Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J. Virol. 61:3672-3679.
24. Takada K, Shimizu N, Sakuma S, Ono Y. 1986. trans activation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV DNA fragment. J. Virol. 57:1016-1022.
25. Bhende PM, Seaman WT, Delecluse HJ, Kenney SC. 2004. The EBV lytic switch protein, Z, preferentially binds to and activates the methylated viral genome. Nat. Genet. 36:1099-1104.
26. Bhende PM, Seaman WT, Delecluse HJ, Kenney SC. 2005. BZLF1 activation of the methylated form of the BRLF1 immediate-early promoter is regulated by BZLF1 residue 186. J. Virol. 79:7338-7348.
27. Dickerson SJ, Xing Y, Robinson AR, Seaman WT, Gruffat H, Kenney SC. 2009. Methylation-dependent binding of the Epstein-Barr virus BZLF1 protein to viral promoters. PLoS Pathog. 5:e1000356. doi:10.1371/journal.ppat.1000356.
28. Wille CK, Nawandar DM, Panfil AR, Ko MM, Hagemeier SR, Kenney SC. 2013. Viral genome methylation differentially affects the ability of BZLF1 versus BRLF1 to activate Epstein-Barr virus lytic gene expression and viral replication. J. Virol. 87:935-950.
29. Bergbauer M, Kalla M, Schmeinck A, Gobel C, Rothbauer U, Eck S, Benet-Pages A, Strom TM, Hammerschmidt W. 2010. CpG-methylation regulates a class of Epstein-Barr virus promoters. PLoS Pathog. 6:e1001114. doi:10.1371/journal.ppat.1001114.
30. Kalla M, Schmeinck A, Bergbauer M, Pich D, Hammerschmidt W. 2010. AP-1 homolog BZLF1 of Epstein-Barr virus has two essential functions dependent on the epigenetic state of the viral genome. Proc. Natl. Acad. Sci. U. S. A. 107:850-855.
31. Flower K, Thomas D, Heather J, Ramasubramanyan S, Jones S, Sinclair AJ. 2011. Epigenetic control of viral life-cycle by a DNA-methylationdependent transcription factor. PLoS One 6:e25922. doi:10.1371/journal.pone.0025922.
32. Fernandez AF, Rosales C, Lopez-Nieva P, Grana O, Ballestar E, Ropero S, Espada J, Melo SA, Lujambio A, Fraga MF, Pino I, Javierre B, Carmona FJ, Acquadro F, Steenbergen RD, Snijders PJ, Meijer CJ, Pineau P, Dejean A, Lloveras B, Capella G, Quer J, Buti M, Esteban JI, Allende H, Rodriguez-Frias F, Castellsague X, Minarovits J, Ponce J, Capello D, Gaidano G, Cigudosa JC, Gomez-Lopez G, Pisano DG, Valencia A, Piris MA, Bosch FX, Cahir-McFarland E, Kieff E, Esteller M. 2009. The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res. 19:438-451.
33. Boyes J, Bird A. 1991. DNA methylation inhibits transcription indirectly via a methyl-CpG binding protein. Cell 64:1123-1134.
34. Boyes J, Bird A. 1992. Repression of genes by DNA methylation depends on CpG density and promoter strength: evidence for involvement of a methyl-CpG binding protein. EMBO J. 11:327-333.
35. Razin A. 1998. CpG methylation, chromatin structure, and gene silencing: a three-way connection. EMBO J. 17:4905-4908.
36. Watt F, Molloy PL. 1988. Cytosine methylation prevents binding to DNA of a HeLa cell transcription factor required for optimal expression of the adenovirus major late promoter. Genes Dev. 2:1136-1143.
37. Medvedovic J, Ebert A, Tagoh H, Busslinger M. 2011. Pax5: a master regulator of B cell development and leukemogenesis. Adv. Immunol. 111: 179-206.
38. Cobaleda C, Schebesta A, Delogu A, Busslinger M. 2007. Pax5: the guardian of B cell identity and function. Nat. Immunol. 8:463-470.
39. Hagman J, Lukin K. 2006. Transcription factors drive B cell development. Curr. Opin. Immunol. 18:127-134.
40. Hagman J, Lukin K. 2005. Early B-cell factor "pioneers" the way for B-cell development. Trends Immunol. 26:455-461.
41. Zhang Z, Espinoza CR, Yu Z, Stephan R, He T, Williams GS, Burrows PD, Hagman J, Feeney AJ, Cooper MD. 2006. Transcription factor Pax5 (BSAP) transactivates the RAG-mediated V(H)-to-DJ(H) rearrangement of immunoglobulin genes. Nat. Immunol. 7:616-624.
42. Xie H, Ye M, Feng R, Graf T. 2004. Stepwise reprogramming of B cells into macrophages. Cell 117:663-676.
43. He T, Hong SY, Huang L, Xue W, Yu Z, Kwon H, Kirk M, Ding SJ, Su K, Zhang Z. 2011. Histone acetyltransferase p300 acetylates Pax5 and strongly enhances Pax5-mediated transcriptional activity. J. Biol. Chem. 286:14137-14145.
44. Schebesta A, McManus S, Salvagiotto G, Delogu A, Busslinger GA, Busslinger M. 2007. Transcription factor Pax5 activates the chromatin of key genes involved in B cell signaling, adhesion, migration, and immune function. Immunity 27:49-63.
45. Schebesta M, Pfeffer PL, Busslinger M. 2002. Control of pre-BCR signaling by Pax5-dependent activation of the BLNK gene. Immunity 17: 473-485.
46. Carotta S, Holmes ML, Pridans C, Nutt SL. 2006. Pax5 maintains cellular identity by repressing gene expression throughout B cell differentiation. Cell Cycle 5:2452-2456.
47. Pridans C, Holmes ML, Polli M, Wettenhall JM, Dakic A, Corcoran LM, Smyth GK, Nutt SL. 2008. Identification of Pax5 target genes in early B cell differentiation. J. Immunol. 180:1719-1728.
48. Revilla IDR, Bilic I, Vilagos B, Tagoh H, Ebert A, Tamir IM, Smeenk L, Trupke J, Sommer A, Jaritz M, Busslinger M. 2012. The B-cell identity factor Pax5 regulates distinct transcriptional programmes in early and late B lymphopoiesis. EMBO J. 31:3130-3146.
49. Tierney R, Nagra J, Hutchings I, Shannon-Lowe C, Altmann M, Hammerschmidt W, Rickinson A, Bell A. 2007. Epstein-Barr virus exploits BSAP/Pax5 to achieve the B-cell specificity of its growth-transforming program. J. Virol. 81:10092-10100.
50. Tierney RJ, Kirby HE, Nagra JK, Desmond J, Bell AI, Rickinson AB. 2000. Methylation of transcription factor binding sites in the Epstein-Barr virus latent cycle promoter Wp coincides with promoter downregulation during virus-induced B-cell transformation. J. Virol. 74:10468-10479.
51. Arvey A, Tempera I, Tsai K, Chen HS, Tikhmyanova N, Klichinsky M, Leslie C, Lieberman PM. 2012. An atlas of the Epstein-Barr virus transcriptome and epigenome reveals host-virus regulatory interactions. Cell Host Microbe 12:233-245.
52. Adamson AL, Wright N, LaJeunesse DR. 2005. Modeling early Epstein-Barr virus infection in Drosophila melanogaster: the BZLF1 protein. Genetics 171:1125-1135.
53. Adamson AL. 2005. Epstein-Barr virus BZLF1 protein binds to mitotic chromosomes. J. Virol. 79:7899-7904.
54. Lin KI, Angelin-Duclos C, Kuo TC, Calame K. 2002. Blimp-1-dependent repression of Pax-5 is required for differentiation of B cells to immunoglobulin M-secreting plasma cells. Mol. Cell. Biol. 22:4771-4780.
55. Shaffer AL, Lin KI, Kuo TC, Yu X, Hurt EM, Rosenwald A, Giltnane JM, Yang L, Zhao H, Calame K, Staudt LM. 2002. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 17:51-62.
56. Hauser J, Verma-Gaur J, Wallenius A, Grundstrom T. 2009. Initiation of antigen receptor-dependent differentiation into plasma cells by calmodulin inhibition of E2A. J. Immunol. 183:1179-1187.
57. Takada K. 1984. Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines. Int. J. Cancer 33:27-32.
58. Shimizu N, Takada K. 1993. Analysis of the BZLF1 promoter of Epstein-Barr virus: identification of an anti-immunoglobulin response sequence. J. Virol. 67:3240-3245.
59. Lo AK, Lo KW, Tsao SW, Wong HL, Hui JW, To KF, Hayward DS, Chui YL, Lau YL, Takada K, Huang DP. 2006. Epstein-Barr virus infection alters cellular signal cascades in human nasopharyngeal epithelial cells. Neoplasia 8:173-180.
60. Glaser R, Zhang HY, Yao KT, Zhu HC, Wang FX, Li GY, Wen DS, Li YP. 1989. Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas. Proc. Natl. Acad. Sci. U. S. A. 86:9524-9528.
61. Menezes J, Leibold W, Klein G, Clements G. 1975. Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. Biomedicine 22:276-284.
62. Graham FL, Smiley J, Russell WC, Nairn R. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36:59-74.
63. Sarisky RT, Gao Z, Lieberman PM, Fixman ED, Hayward GS, Hayward SD. 1996. A replication function associated with the activation domain of the Epstein-Barr virus Zta transactivator. J. Virol. 70:8340-8347.
64. Fitzsimmons D, Hodsdon W, Wheat W, Maira SM, Wasylyk B, Hagman J. 1996. Pax-5 (BSAP) recruits Ets proto-oncogene family proteins to form functional ternary complexes on a B-cell-specific promoter. Genes Dev. 10:2198-2211.
65. Robinson AR, Kwek SS, Kenney SC. 2012. The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1. PLoS Pathog. 8:e1002516. doi:10.1371/journal.ppat.1002516.
66. Rhee JM, Trieu M, Turner EE. 2001. Optimal Oct-2 affinity for an extended DNA site and the effect of GST fusion on site preference. Arch. Biochem. Biophys. 385:397-405.
67. Gisler R, Akerblad P, Sigvardsson M. 1999. A human early B-cell factorlike protein participates in the regulation of the human CD19 promoter. Mol. Immunol. 36:1067-1077.
68. Klug M, Rehli M. 2006. Functional analysis of promoter CpG methylation using a CpG-free luciferase reporter vector. Epigenetics 1:127-130.
69. Delecluse HJ, Hilsendegen T, Pich D, Zeidler R, Hammerschmidt W. 1998. Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc. Natl. Acad. Sci. U. S. A. 95:8245-8250.
70. Swenson JJ, Holley-Guthrie E, Kenney SC. 2001. Epstein-Barr virus immediate-early protein BRLF1 interacts with CBP, promoting enhanced BRLF1 transactivation. J. Virol. 75:6228-6234.
71. Adler B, Schaadt E, Kempkes B, Zimber-Strobl U, Baier B, Bornkamm GW. 2002. Control of Epstein-Barr virus reactivation by activated CD40 and viral latent membrane protein 1. Proc. Natl. Acad. Sci. U. S. A. 99: 437-442.
72. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, Girtman K, Mathew S, Ma J, Pounds SB, Su X, Pui CH, Relling MV, Evans WE, Shurtleff SA, Downing JR. 2007. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446:758-764.
73. Kurahashi S, Hayakawa F, Miyata Y, Yasuda T, Minami Y, Tsuzuki S, Abe A, Naoe T. 2011. PAX5-PML acts as a dual dominant-negative form of both PAX5 and PML. Oncogene 30:1822-1830.
74. Buettner M, Lang A, Tudor CS, Meyer B, Cruchley A, Barros MH, Farrell PJ, Jack HM, Schuh W, Niedobitek G. 2012. Lytic Epstein-Barr virus infection in epithelial cells but not in B lymphocytes is dependent on Blimp1. J. Gen. Virol. 93:1059-1064